Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Circassia Pharmaceuticals ( (GB:NIOX) ) just unveiled an update.
NIOX Group plc has confirmed that as of 31 December 2025 its issued share capital consists of 417,896,847 ordinary shares, each carrying one voting right, with no shares held in treasury. The updated total follows the exercise of employee options over 17,730 ordinary shares under the company’s share option schemes, with the new shares admitted from existing block listings and ranking equally with existing stock, providing shareholders with an updated denominator for calculating disclosure thresholds under FCA transparency rules.
The most recent analyst rating on (GB:NIOX) stock is a Hold with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven by its strong financial performance and positive corporate events, which are offset by neutral technical indicators and a high P/E ratio suggesting overvaluation. The company’s robust cash flow and low leverage provide a stable foundation, while recent corporate actions signal confidence in future growth.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
NIOX Group plc is a UK-listed company on AIM that operates within the healthcare sector, with its activities centred around its issued ordinary share capital and equity-related governance as part of a publicly traded corporate structure.
Average Trading Volume: 976,665
Technical Sentiment Signal: Hold
Current Market Cap: £275.8M
Learn more about NIOX stock on TipRanks’ Stock Analysis page.